Pfizer's breast cancer drug draws Wall Street's interest
This article was originally published in Scrip
Executive Summary
Pfizer’s experimental breast cancer treatment, recently renamed palbociclib, is beginning to excite Wall Street analysts looking for a much-needed blockbuster from the US pharmaceutical giant.